Actinium Pharmaceuticals Details
Actinium Pharmaceuticals (NYSE: ATNM) is focused on developing innovative targeted radioimmunotherapies for the treatment of advanced cancers. Currently Investigating therapies in #AML and #BMT
Employees:
50 - 99
HQ:
646-840-5442
Location:
New York, NY, US
Revenue:
5 - 10 Million
Alpha Particle Immunotherapeutics for Cancer
Acute Myeloid Leukemia
Hematopoetic Stem and Cell Transplationation
Biopharmaceuticals
Radioimmunotherapy
Hematopoeitic Stem Cell and Bone Marrow Transplant
Biopharmaceuticals and ADC's
Biopharmaceuticals and ADC's
Myeloablation
Multiple Myeloma
BioTech/Drugs
Commercial Physical Research
Biotechnology